This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HCA Healthcare (HCA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 4.19% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
HCA Healthcare Pre-Q4 Earnings: Golden Opportunity or Fool's Gold?
by Zacks Equity Research
HCA's fourth-quarter results are expected to benefit from rising admissions and patient days. However, increasing expenses are a concern.
What Analyst Projections for Key Metrics Reveal About HCA (HCA) Q4 Earnings
by Zacks Equity Research
Evaluate the expected performance of HCA (HCA) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
HCA Healthcare (HCA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health Stock Trading at Attractive Valuation: Time to Buy?
by Kaibalya Pravo Dey
With UHS stock trading at a discount, we examine its growth drivers and challenges to determine if it presents a strong investment opportunity for investors at this time.
Top Analyst Reports for Microsoft, Exxon Mobil & Amgen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil Corporation (XOM) and Amgen Inc. (AMGN), as well as two micro-cap stocks PrimeEnergy Resources Corporation (PNRG) and FONAR Corporation (FONR).
Should You Buy Tenet Healthcare Stock Now at Cheaper Valuation?
by Kaibalya Pravo Dey
As occupancy levels rise and resource utilization grows, THC's operating costs are expected to continue increasing.
HCA Healthcare Stock Trades at Premium: Time to Buy or Hold?
by Kaibalya Pravo Dey
HCA's strong cash-generating abilities are expected to improve its financial position.
3 Sector ETFs & Stocks to Gain On Upbeat November Jobs Data
by Sanghamitra Saha
The U.S. economy added 227, 000 jobs in November 2024, beating forecasts of 200, 000.
Why Now is the Time to Buy Tenet Stock After a 15% Drop
by Kaibalya Pravo Dey
THC's cheaper valuation, combined with strong earnings growth and robust free cash flow, makes it an appealing pick for value investors.
Universal Health Up 46% in a Year: Is it the Right Time to Invest?
by Zacks Equity Research
UHS gains from growing patient volumes and an extensive treatment network. However, an elevated expense level can pressure margins in the days ahead.
Top Research Reports for Amazon, Stryker & Lam Research
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Stryker Corporation (SYK) and Lam Research Corporation (LRCX), as well as a micro-cap stock, ImmuCell Corporation (ICCC).
Tenet Healthcare Partners With Commure for Ambient AI Platform
by Zacks Equity Research
THC actively invests in selected AI-enabled technologies, which are expected to enhance the clinical and administrative workflow and efficiency.
Zacks Industry Outlook HCA Healthcare, Tenet Healthcare, Universal Health, Acadia Healthcare and Community Health Systems
by Zacks Equity Research
HCA Healthcare, Tenet Healthcare, Universal Health, Acadia Healthcare and Community Health Systems have been highlighted in this Industry Outlook article.
5 Hospital Stocks Set to Thrive Amid Robust Industry Trends
by Zacks Equity Research
The Zacks Medical-Hospital industry is likely to gain from rising patient admissions and technological advancements. Companies like HCA, THC, UHS, ACHC and CYH are poised to gain from these trends.
HCA Healthcare Stock Up 12.7% in 6 Months: What Should Investors Do?
by Zubia Masood
HCA is expected to benefit from growing volumes and operational efficiency. However, declining outpatient surgeries and the impact of hurricanes might partially offset the positives.
Tenet Stock Jumps 19.6% Since Q3 Results: What Should Investors Do?
by Kaibalya Pravo Dey
THC continues to experience strong demand for its services, which is expected to continue throughout the year.
Acadia Healthcare Shares Down 18.7% Despite Q3 Earnings Beat
by Zacks Equity Research
ACHC's better-than-expected third-quarter earnings benefit from higher patient days and improving volumes. Closing two facilities led the company to reduce its 2024 revenue guidance.
Select Medical Up 13.8% Since Q3 Earnings Top on Patient Day Growth
by Zacks Equity Research
SEM's strong third-quarter results benefit from improving patient days and admissions in the Rehabilitation Hospital segment. Elevated expenses partially offset the positives.
Analyzing Universal Health's Q3 Earnings: To Buy or Keep Your Cool?
by Debasmita Chatterjee
UHS is well-poised to benefit from growing patient volumes and extensive treatment network, partly offset by elevated operating costs.
Tenet Q3 Earnings Beat on Strong Ambulatory Unit, '24 EPS View Raised
by Zacks Equity Research
THC's Q3 results benefit from higher same-hospital admissions and Medicaid supplemental revenue gains. Cost-cutting measures help offset challenges from hospital divestitures.
Should You Buy, Hold or Sell HCA Healthcare Stock After Q3 Earnings?
by Zubia Masood
HCA is poised to benefit from volume growth and expansion initiatives.
HCA Healthcare Beats on Q3 Earnings, Reaffirms 2024 EPS View
by Zacks Equity Research
HCA's quarterly results benefit from improved admissions and inpatient surgeries, partially offset by the impact of hurricanes and rising salaries and benefits expenses.
A Dose of Growth? Why Tenet Healthcare Could be a Buy Pre-Q3 Earnings
by Kaibalya Pravo Dey
THC's third-quarter results are likely to reflect growing patient admissions, utilization and patient days.
HCA (HCA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.